MedTrace Logo

ENCOrafenib With Binimetinib in bRAF NSCLC

NCT04526782 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2025-11-18

No results posted yet for this study

Summary

A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

Conditions

  • Non Small Cell Lung Cancer
  • BRAF V600E

Interventions

DRUG

Encorafenib 75 MG

450 mg (6 × 75 mg capsule) per day

DRUG

Binimetinib 15 MG

45 mg (3 × 15 mg tablet) twice daily

Sponsors & Collaborators

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • David Planchard · Gustave Roussy (Villejuif - France)

  • Charles Ricordel · CHU Rennes,France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-19
Primary Completion
2025-07-16
Completion
2026-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04526782 on ClinicalTrials.gov